Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker BNTX · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe a… NCT07111520 · Non-small Cell Lung Cancer BNT326, Pumitamig | BNTX BioNTech SE | Phase 1/2 | Recruiting | 880 | Nov 2028 | Registry ↗ |
| Nov 10, 2026 | A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used i… NCT06827236 · Locally Advanced Breast Cancer, Unresectable Breast Carcino… BNT323, BNT327 | BNTX BioNTech SE | Phase 1/2 | Recruiting | 380 | Aug 2029 | Registry ↗ |
| Nov 10, 2026 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patien… NCT06340568 · Endometrial Cancer BNT323/DB-1303, Doxorubicin | BNTX BioNTech SE | Phase 3 | Recruiting | 480 | Mar 2028 | Registry ↗ |
| Nov 10, 2026 | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combi… NCT04534205 · Unresectable Head and Neck Squamous Cell Carcinoma, Metasta… BNT113, Pembrolizumab | BNTX BioNTech SE | Phase 2/3 | Active, not recruiting | 358 | Apr 2029 | Registry ↗ |
| Nov 6, 2026 | Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cel… NCT06449209 · Extensive-stage Small-cell Lung Cancer, Small-cell Lung Can… BNT327 Dose Level 1 (DL1), BNT327 Dose Level 2 (DL2) | BNTX BioNTech SE | Phase 2 | Active, not recruiting | 110 | Jun 2027 | Registry ↗ |
| Nov 2, 2026 | Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investi… NCT06712316 · Non-small Cell Lung Cancer Pumitamig, Pembrolizumab | BNTX BioNTech SE | Phase 2/3 | Recruiting | 1,580 | Jan 2029 | Registry ↗ |
| Oct 30, 2026 | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Canc… NCT07173751 · Breast Neoplasms Pumitamig, Nab-paclitaxel/Paclitaxel | BNTX BioNTech SE | Phase 3 | Recruiting | 558 | Dec 2029 | Registry ↗ |
| Oct 28, 2026 | A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it… NCT07297212 · Recurrent Glioblastoma Pumitamig, Bevacizumab | BNTX BioNTech SE | Phase 2 | Recruiting | 75 | Jan 2028 | Registry ↗ |
| Oct 23, 2026 | A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially… NCT07893054 · Advanced Solid Tumors BNT3219 | BNTX BioNTech SE | Phase 1 | Not yet recruiting | 207 | Jul 2029 | Registry ↗ |
| Oct 22, 2026 | A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Sa… NCT05432583 · Genital Herpes Simplex Type 2 BNT163, Placebo | BNTX BioNTech SE | Phase 1 | Active, not recruiting | 318 | Oct 2026 | Registry ↗ |
| Oct 21, 2026 | A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for… NCT07886684 · Advanced Solid Tumors BNT3210 | BNTX BioNTech SE | Phase 1/2 | Not yet recruiting | 173 | Oct 2029 | Registry ↗ |
| Oct 16, 2026 | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer NCT07365995 · Metastatic Castration-resistant Prostate Cancer BNT324, Docetaxel | BNTX BioNTech SE | Phase 3 | Recruiting | 736 | Feb 2031 | Registry ↗ |
| Oct 16, 2026 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age NCT07300839 · COVID-19, SARS-COV-2 Infection BNT162b2 Vaccine, Placebo | BNTX BioNTech SE | Phase 3 | Completed | 5,240 | Sep 22, 2026 | Registry ↗ |
| Oct 15, 2026 | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for… NCT07186842 · Advanced Solid Cancers BNT329, CA19-9-targeting monoclonal antibody | BNTX BioNTech SE | Phase 1/2 | Recruiting | 245 | May 2030 | Registry ↗ |
| Oct 14, 2026 | A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adul… NCT07698600 · HIV -1 Infection BNT168, Placebo | BNTX BioNTech SE | Phase 1 | Recruiting | 126 | Feb 2028 | Registry ↗ |
| Oct 14, 2026 | Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Pati… NCT06712355 · Extensive-stage Small-cell Lung Cancer Pumitamig, Atezolizumab | BNTX BioNTech SE | Phase 3 | Recruiting | 621 | Apr 2029 | Registry ↗ |
| Oct 9, 2026 | A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Bene… NCT07070232 · Advanced Solid Tumor BNT326, Pumitamig | BNTX BioNTech SE | Phase 1/2 | Recruiting | 1,438 | Mar 2028 | Registry ↗ |
| Oct 7, 2026 | A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients W… NCT04486378 · Colorectal Cancer Stage II, Colorectal Cancer Stage III RO7198457 intravenous (IV), Observational group (no interve… | BNTX BioNTech SE | Phase 2 | Active, not recruiting | 327 | Nov 2026 | Registry ↗ |
| Oct 5, 2026 | A First-in-human Safety Trial of BNT331 Administered as Single Ascending Doses in Healthy Women and… NCT06469164 · Bacterial Vaginosis BNT331, Placebo | BNTX BioNTech SE | Phase 1 | Completed | 102 | Jul 31, 2025 | Registry ↗ |
| Sep 28, 2026 | A Study of COVID-19 Vaccine(s) in Children and Adults NCT07798648 · COVID-19 Vaccines BNT162b2, BNT162b2 | BNTX BioNTech SE | Phase 3 | Recruiting | 700 | Apr 21, 2027 | Registry ↗ |
| Sep 15, 2026 | Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors NCT06150183 · Advanced Malignant Solid Tumor BNT314 | BNTX BioNTech SE | Phase 1 | Active, not recruiting | 41 | Aug 18, 2026 | Registry ↗ |
| Sep 15, 2026 | A Clinical Study Investigating the Safety and Immune Responses After Immunization With Investigatio… NCT05988203 · Monkeypox BNT166a | BNTX BioNTech SE | Phase 1/2 | Completed | 96 | Aug 25, 2025 | Registry ↗ |
| Sep 9, 2026 | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors NCT06750185 · Advanced Solid Tumor BNT317 DL1, BNT317 DL2 | BNTX BioNTech SE | Phase 1/2 | Recruiting | 248 | Apr 2031 | Registry ↗ |
| Sep 1, 2026 | A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults… NCT07392372 · HIV -1 Infection BNT351, Placebo | BNTX BioNTech SE | Phase 1 | Recruiting | 67 | Nov 2026 | Registry ↗ |
| Aug 28, 2026 | A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an In… NCT06069544 · Malaria BNT165c, BNT165d | BNTX BioNTech SE | Phase 1/2 | Completed | 163 | May 28, 2025 | Registry ↗ |
| Aug 26, 2026 | A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy W… NCT06892548 · Advanced Lung Cancer BNT324, BNT327 | BNTX BioNTech SE | Phase 1/2 | Recruiting | 594 | Sep 2028 | Registry ↗ |
| Aug 19, 2026 | A Study to Learn About Flu and COVID-19 Vaccine Responses in Healthy People NCT06683352 · Influenza,Human, COVID-19 Investigational Influenza Vaccine, COVID-19 Vaccine | BNTX BioNTech SE | Phase 1/2 | Completed | 1,353 | Jul 15, 2025 | Registry ↗ |
| Aug 13, 2026 | Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced… NCT07455734 · Advanced Solid Tumor Cancer BNT3214 | BNTX BioNTech SE | Phase 1/2 | Recruiting | 533 | Oct 2030 | Registry ↗ |
| Aug 11, 2026 | A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immu… NCT07379580 · Mpox (Monkeypox), Smallpox BNT166a, Placebo | BNTX BioNTech SE | Phase 2 | Recruiting | 310 | Jun 2027 | Registry ↗ |
| Aug 7, 2026 | A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age NCT07730450 · COVID-19 Vaccines BNT162b2 Vaccine, Tdap Vaccine | BNTX BioNTech SE | Phase 4 | Recruiting | 200 | Aug 20, 2027 | Registry ↗ |
| Aug 7, 2026 | A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 1… NCT07222384 · COVID-19, SARS-COV-2 Infection BNT162b2 (2025/2026 formulation) | BNTX BioNTech SE | Phase 3 | Completed | 344 | Jul 24, 2026 | Registry ↗ |
| Aug 6, 2026 | A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children NCT05543616 · SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronav… Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram… | BNTX BioNTech SE | Phase 3 | Completed | 4,338 | Jul 10, 2026 | Registry ↗ |
| Jul 28, 2026 | A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works Wh… NCT07255404 · Pancreatic Ductal Adenocarcinoma (PDAC) Pumitamig, Nab-paclitaxel | BNTX BioNTech SE | Phase 2 | Recruiting | 105 | Dec 2027 | Registry ↗ |
| Jul 22, 2026 | Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in… NCT05142189 · Non-Small Cell Lung Cancer BNT116, Cemiplimab | BNTX BioNTech SE | Phase 1 | Recruiting | 320 | Feb 2030 | Registry ↗ |
| Jul 1, 2026 | A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination Wit… NCT07079631 · Metastatic Colorectal Cancer BNT314, Pumitamig | BNTX BioNTech SE | Phase 1/2 | Recruiting | 482 | Dec 2030 | Registry ↗ |
| Jun 30, 2026 | Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When… NCT06449222 · Locally Advanced Breast Cancer, Triple Negative Breast Canc… BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2) | BNTX BioNTech SE | Phase 2 | Active, not recruiting | 83 | Aug 2028 | Registry ↗ |
| Jun 15, 2026 | A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Co… NCT07147348 · Advanced Solid Tumor BNT3212, Pumitamig | BNTX BioNTech SE | Phase 1/2 | Recruiting | 375 | Nov 2027 | Registry ↗ |
| Jun 1, 2026 | A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 i… NCT07069309 · COVID-19, SARS-COV-2 Infection BNT162b2 (2025/2026 recommended SARS-CoV-2 strain) | BNTX BioNTech SE | Phase 3 | Completed | 774 | May 1, 2026 | Registry ↗ |
| May 28, 2026 | Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against… NCT04816643 · SARS-CoV-2 Infection, COVID-19 Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg | BNTX BioNTech SE | Phase 3 | Completed | 11,837 | Oct 4, 2023 | Registry ↗ |
| May 22, 2026 | Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III… NCT04813627 · Colorectal Cancer Stage II, Colorectal Cancer Stage III Regular blood sample collection for ctDNA assessment | BNTX BioNTech SE | — | Completed | 2,079 | Apr 23, 2025 | Registry ↗ |
| Apr 28, 2026 | A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals NCT05997290 · SARS-CoV-2 Infection, COVID-19 BNT162b2 (Omi XBB.1.5), BNT162b2 (Omi JN.1) | BNTX BioNTech SE | Phase 2/3 | Completed | 1,051 | Mar 13, 2025 | Registry ↗ |
| Apr 24, 2026 | Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With… NCT06841055 · Non-small Cell Lung Cancer Pumitamig, Docetaxel | BNTX BioNTech SE | Phase 2 | Recruiting | 60 | Oct 2028 | Registry ↗ |
| Apr 8, 2026 | Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors NCT05262530 · Solid Tumor BNT142 | BNTX BioNTech SE | Phase 1/2 | Terminated | 73 | Dec 22, 2025 | Registry ↗ |
| Mar 25, 2026 | Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates… NCT04368728 · SARS-CoV-2 Infection, COVID-19 BNT162b1, BNT162b2 | BNTX BioNTech SE | Phase 2/3 | Completed | 46,969 | Feb 10, 2023 | Registry ↗ |
| Mar 20, 2026 | Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population NCT04649021 · SARS-CoV-2 BNT162b2, Placebo | BNTX BioNTech SE | Phase 2 | Completed | 960 | Feb 7, 2021 | Registry ↗ |
| Mar 18, 2026 | Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against T… NCT05547464 · Tuberculosis BNT164a1, BNT164b1 | BNTX BioNTech SE | Phase 1/2 | Active, not recruiting | 497 | Mar 12, 2026 | Registry ↗ |
| Mar 13, 2026 | RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID NCT02316457 · Breast Cancer (Triple Negative Breast Cancer (TNBC)) IVAC_W_bre1_uID, IVAC_W_bre1_uID/IVAC_M_uID | BNTX BioNTech SE | Phase 1 | Completed | 42 | May 13, 2020 | Registry ↗ |
| Mar 12, 2026 | Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients Wi… NCT02410733 · Melanoma Lipo-MERIT | BNTX BioNTech SE | Phase 1 | Completed | 119 | Jun 20, 2023 | Registry ↗ |
| Jan 26, 2026 | A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People NCT06821061 · Influenza, COVID-19 (Coronavirus Disease 2019) Investigational Influenza Vaccine, Investigational COVID-19… | BNTX BioNTech SE | Phase 1/2 | Completed | 2,650 | Dec 17, 2025 | Registry ↗ |
| Jan 13, 2026 | Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People NCT05541861 · SARS-CoV-2 Infection, COVID-19 BNT162b2 Bivalent (original/Omicron BA.4/BA.5) 30 mcg, BNT1… | BNTX BioNTech SE | Phase 1 | Completed | 383 | Nov 22, 2024 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:18 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances